558 related articles for article (PubMed ID: 32246147)
1. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
Karlowsky JA; Lob SH; Raddatz J; DePestel DD; Young K; Motyl MR; Sahm DF
Clin Infect Dis; 2021 Jun; 72(12):2112-2120. PubMed ID: 32246147
[TBL] [Abstract][Full Text] [Related]
2.
Karlowsky JA; Lob SH; DeRyke CA; Hilbert DW; Wong MT; Young K; Siddiqui F; Motyl MR; Sahm DF
Antimicrob Agents Chemother; 2022 May; 66(5):e0018922. PubMed ID: 35491836
[TBL] [Abstract][Full Text] [Related]
3. In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017.
Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
Int J Antimicrob Agents; 2020 Jan; 55(1):105841. PubMed ID: 31704217
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of imipenem/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015-2017.
Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
J Glob Antimicrob Resist; 2020 Jun; 21():223-228. PubMed ID: 31698105
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Sader HS; Castanheira M; Duncan LR; Mendes RE
Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
[TBL] [Abstract][Full Text] [Related]
6. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016 and 2019 in China.
Yu W; Zhang H; Zhu Y; Jia P; Xu Y; Yang Q
Int J Antimicrob Agents; 2023 Apr; 61(4):106741. PubMed ID: 36736928
[TBL] [Abstract][Full Text] [Related]
7. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and
Karlowsky JA; Lob SH; Hawser SP; Kothari N; Siddiqui F; Alekseeva I; DeRyke CA; Young K; Motyl MR; Sahm DF
JAC Antimicrob Resist; 2023 Aug; 5(4):dlad098. PubMed ID: 37577157
[TBL] [Abstract][Full Text] [Related]
8. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Activity of Imipenem/Relebactam Against Gram-Negative Bacilli from Pediatric Patients-Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance program 2015-2017.
Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
J Pediatric Infect Dis Soc; 2021 Apr; 10(3):274-281. PubMed ID: 32535630
[TBL] [Abstract][Full Text] [Related]
10.
Lob SH; Karlowsky JA; Young K; Motyl MR; Hawser S; Kothari ND; Sahm DF
J Med Microbiol; 2020 Feb; 69(2):207-217. PubMed ID: 31976856
[No Abstract] [Full Text] [Related]
11. Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates-SMART United States 2019-21.
Karlowsky JA; Lob SH; Bauer KA; Esterly J; Siddiqui F; Young K; Motyl MR; Sahm DF
JAC Antimicrob Resist; 2024 Feb; 6(1):dlad152. PubMed ID: 38222461
[TBL] [Abstract][Full Text] [Related]
12. Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016.
Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
J Glob Antimicrob Resist; 2018 Dec; 15():140-147. PubMed ID: 30071354
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of gram-negative isolates collected in Taiwan to imipenem/relebactam and comparator agents - SMART 2018-2021.
Wise MG; Karlowsky JA; Chen WT; Siddiqui F; Young K; Motyl MR; Sahm DF
J Formos Med Assoc; 2024 Mar; 123(3):400-407. PubMed ID: 37735013
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva D; Chaves C; Pássaro L; Paixão L; Cantón R;
Int J Antimicrob Agents; 2020 Mar; 55(3):105887. PubMed ID: 31926283
[TBL] [Abstract][Full Text] [Related]
15. Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018.
Pfaller MA; Shortridge D; Harris KA; Garrison MW; DeRyke CA; DePestel DD; Moise PA; Sader HS
Int J Infect Dis; 2021 Nov; 112():321-326. PubMed ID: 34597763
[TBL] [Abstract][Full Text] [Related]
16. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
[No Abstract] [Full Text] [Related]
17. Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18.
Sader HS; Carvalhaes CG; Duncan LR; Flamm RK; Shortridge D
J Antimicrob Chemother; 2020 Oct; 75(10):2907-2913. PubMed ID: 32653914
[TBL] [Abstract][Full Text] [Related]
18. Moving towards a standardized definition of antimicrobial resistance: a comparison of the antimicrobial susceptibility profile of difficult-to-treat resistance (DTR) versus multidrug-resistant (MDR) Pseudomonas aeruginosa clinical isolates (CANWARD, 2016-2021).
Walkty A; Karlowsky JA; Lagacé-Wiens PRS; Baxter MR; Adam HJ; Bay DC; Zhanel GG
Diagn Microbiol Infect Dis; 2024 Feb; 108(2):116130. PubMed ID: 38006710
[TBL] [Abstract][Full Text] [Related]
19.
Karlowsky JA; Lob SH; Siddiqui F; Akrich B; DeRyke CA; Young K; Motyl MR; Hawser SP; Sahm DF
J Med Microbiol; 2023 Feb; 72(2):. PubMed ID: 36763081
[No Abstract] [Full Text] [Related]
20.
Schmidt-Malan SM; Mishra AJ; Mushtaq A; Brinkman CL; Patel R
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29760145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
